Back to top
more

Arcus Biosciences (RCUS)

(Delayed Data from NYSE)

$14.68 USD

14.68
450,974

+0.09 (0.62%)

Updated Apr 22, 2024 04:00 PM ET

After-Market: $14.67 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for RCUS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Arcus Biosciences, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 759 1,009 499 729 188
Receivables 38 39 747 2 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 34 19 16 5 4
Total Current Assets 831 1,067 1,262 736 193
Net Property & Equipment 51 35 32 11 9
Investments & Advances 107 129 182 6 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 106 114 11 6 1
Total Assets 1,095 1,345 1,592 772 203
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 17 20 10 16 5
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 54 28 10
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 167 173 102 78 8
Total Current Liabilities 184 193 166 122 23
Mortgages 0 0 0 0 0
Deferred Taxes/Income 307 355 462 123 12
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 142 140 5 10 5
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 633 688 750 270 39
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1,311 1,206 0 0 0
Capital Surplus 0 0 1,118 830 369
Retained Earnings -849 -542 -275 -328 -205
Other Equity 0 -7 -1 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 462 657 841 502 164
Total Liabilities & Shareholder's Equity 1,095 1,345 1,592 772 203
Total Common Equity 462 657 841 502 164
Shares Outstanding 74.80 72.40 70.20 64.90 45.80
Book Value Per Share 6.18 9.07 11.99 7.74 3.58

Fiscal Year End for Arcus Biosciences, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 759 799 930 954
Receivables NA 38 52 34 33
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 34 31 22 28
Total Current Assets NA 831 882 986 1,015
Net Property & Equipment NA 51 50 45 37
Investments & Advances NA 107 151 80 90
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 106 108 109 112
Total Assets NA 1,095 1,191 1,220 1,254
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 17 17 12 28
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 167 183 168 151
Total Current Liabilities NA 184 200 180 179
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 307 326 330 330
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 145 144 145
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 633 671 654 654
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1,311 1,291 1,267 1,226
Capital Surplus NA 0 0 0 0
Retained Earnings NA -849 -768 -697 -622
Other Equity NA 0 -3 -4 -4
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 462 520 566 600
Total Liabilities & Shareholder's Equity NA 1,095 1,191 1,220 1,254
Total Common Equity 0 462 520 566 600
Shares Outstanding 90.80 74.80 74.50 73.10 73.00
Book Value Per Share 0.00 6.18 6.98 7.74 8.22